Stoke Therapeutics, INC Form 4 insider transactions

Director Adrian Krainer of Stoke Therapeutics, Inc. was granted stock options on June 5, 2024, according to a Form 4 filing with the SEC.

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Huw M. Nash, COO & CBO of Stoke Therapeutics, exercised stock options and sold 50,000 shares of common stock on May 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Stoke Therapeutics CEO Edward M. Kaye sold shares of common stock on May 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Jonathan Allan, General Counsel of Stoke Therapeutics, reports the sale of 8,599 shares of common stock on May 20, 2024, according to a Form 4 filing.

Thomas Leggett, CFO of Stoke Therapeutics, was granted stock options for 396,200 shares on May 15, 2024.

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, exercised stock options and sold 10,000 shares of common stock on May 1, 2024, according to a Form 4 filing.

Skorpios Trust, along with related entities, reports the sale of 3,600,000 shares of Stoke Therapeutics at $11.60 per share.

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Huw M. Nash, COO & CBO of Stoke Therapeutics, exercised stock options and sold a portion of the acquired shares on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Jonathan Allan, General Counsel of Stoke Therapeutics, sold shares of common stock on March 28, 2024, according to a Form 4 filing with the SEC.

Stephen Tulipano, CFO of Stoke Therapeutics, reports acquisition and disposal of common stock and restricted stock units.

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.

Huw M. Nash, COO & CBO of Stoke Therapeutics, reports acquisition and disposal of common stock and vesting of restricted stock units.

CEO Edward M. Kaye sold shares of Stoke Therapeutics to cover tax withholding liabilities related to the vesting of restricted stock units.

Jonathan Allan, General Counsel & Corp Sec of Stoke Therapeutics, reports acquisition and disposal of common stock and restricted stock units.

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.